MANKIND CMP 2616 TARGET 2656, SL 2587

MANKIND CMP 2616 TARGET 2656, SL 2587

The stock opened below the support zone but recovered smartly and it gave a breakout above the price of Rs.2603 and hence keeps a potential of hitting a price level of Rs.2656 with a risk below Rs.2587.

Mankind Pharma's financial performance showcases consistent growth in revenue and net profit over the years. The consolidated quarterly revenue increased steadily from Rs 2,441.10 Crore in March 2024 to Rs 3,079.37 Crore in March 2025. The net profit has fluctuated, with a recent figure of Rs 422.33 Crore in March 2025. The consolidated yearly revenue for Mankind Pharma has significantly increased from Rs 6,214.43 Crore in 2021 to Rs 12,207.44 Crore in 2025, reflecting a substantial growth of 96.44%. The net profit has also shown considerable growth, rising from Rs 1,281.36 Crore in 2021 to Rs 1,998.88 Crore in 2025. Earnings per share (EPS) have risen from Rs 31.59 in 2021 to Rs 49.28 in 2025. The standalone annual income statement for Mankind Pharma reveals sales of Rs 9,497 Crore in March 2025, compared to Rs 9,264 Crore in March 2024. The net profit stood at Rs 1,945 Crore in March 2025, up from Rs 1,823 Crore in March 2024.